Amyris, Inc. (NASDAQ:AMRS) Files An 8-K Material Modification to Rights of Security Holders
Item 3.03
|
Material Modification to Rights of Security Holders. |
To the extent required by Item 3.03 of Form 8-K, the information
contained in Item 8.01 below is incorporated herein by reference.
| Item 5.03 |
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. |
The information contained in Item8.01 below is incorporated
herein by reference.
| Item 7.01 | Regulation FD Disclosure. |
On June 6, 2017, Amyris, Inc. (the
Company) issued a press release
regarding the matters discussed herein.
The information in this Item 7.01 to Current Report on Form 8-K
and the Exhibit 99.1 attached hereto is furnished to the rules
and regulations of the Securities and Exchange Commission (the
SEC) and shall not be deemed filed for
purposes of Section 18 of the Securities Exchange Act of 1934
(the Exchange Act) or otherwise subject
to the liabilities of that section, nor shall it be deemed
incorporated by reference in any filing under the Securities Act
of 1933, as amended, or the Exchange Act, except as expressly set
forth by specific reference in such a filing.
| Item 8.01 | Other Events. |
On June 5, 2017, the Company filed a Certificate of Amendment of
the Restated Certificate of Incorporation (the
Certificate of Amendment) with the
Secretary of State of Delaware to effect a fifteen-to-one reverse
stock split of the shares of the Companys common stock, par value
$0.0001 per share (the Common Stock),
effective as of the close of business, Eastern Time, on June 5,
2017 (the Reverse Stock Split), as well
as a reduction in the total number of authorized shares of Common
Stock from 500,000,000 to 250,000,000 (the Authorized
Share Reduction). As previously reported, the
Companys stockholders approved the amendment to the Companys
Restated Certificate of Incorporation to effect the Reverse Stock
Split and the Authorized Share Reduction at the Companys 2017
Annual Meeting of Stockholders held on May 23, 2017. The approval
of the Reverse Stock Split and the Authorized Share Reduction by
the Companys stockholders was previously reported in a Current
Report on Form 8-K filed by the Company with the SEC on May 25,
2017, which is incorporated herein by reference. The Reverse
Stock Split and the Authorized Share Reduction are further
described in the Companys definitive proxy statement on Schedule
14Afiled by the Company with the SEC on April 27, 2017, and all
of such disclosure is incorporated herein by reference.
The Common Stock will begin trading on a reverse stock
split-adjusted basis on The NASDAQ Global Select Market on June
6, 2017. The trading symbol for the Common Stock will remain
AMRS. The new CUSIP number for the Common Stock following the
Reverse Stock Split is 03236M200.
| Item 9.01 | Financial Statements and Exhibits. |
(d)Exhibits
The following exhibit is furnished herewith:
| Exhibit Number | Description | |
| 99.1 | Press release, dated June 6, 2017 |
About Amyris, Inc. (NASDAQ:AMRS)
Amyris, Inc. is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels. The Company focuses on a renewable hydrocarbon molecule called farnesene (Biofene). The Company is expanding its range of products across various categories divided into consumer and industrial applications. For consumer applications, the Company is developing and selling personal care products (which include ingredients for cosmetics and F&F), healthcare products and formulated end user products, such as Biossance brand skincare products and Muck Daddy brand hand cleaner product.
